SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase

The latest announcement is out from SynAct Pharma AB ( (SE:SYNACT) ).

SynAct Pharma will present and hold partnering meetings at the BIO-Europe Spring 2026 conference in Lisbon, using the high-profile investor and business development forum to showcase its lead candidate resomelagon for rheumatoid arthritis. The company is positioning resomelagon as an add-on to methotrexate in newly diagnosed patients with high disease activity, ahead of expected Phase 2B topline results in the second quarter, in a bid to secure collaborations and strengthen its position in the inflammatory disease market.

Management emphasizes that resomelagon’s differentiated mechanism could expand treatment options without increasing immune suppression risk, a key consideration for clinicians and patients in rheumatoid arthritis. By engaging with pharmaceutical, biotech, and finance delegates at one of the sector’s major partnering events, SynAct aims to raise its profile, attract strategic partners, and potentially accelerate the development and commercialization pathway for its inflammation-resolution platform.

The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that targets the resolution of inflammation via selective activation of the melanocortin system. Its pipeline comprises oral and injectable selective melanocortin agonists designed to deliver anti-inflammatory and pro-resolution effects, aiming to restore immune balance in patients with inflammatory diseases.

Average Trading Volume: 176,701

Technical Sentiment Signal: Sell

Current Market Cap: SEK948.2M

See more data about SYNACT stock on TipRanks’ Stock Analysis page.